Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 1-A Offering statement
- PART II AND III Part II and III
- 2 Exhibit 2A: Certificate of Incorporation, Certificate of Designation, Certificate of Conversion
- 2 Exhibit 2B: Bylaws
- 3 Exhibit 3: Instruments Defining the Rights of Security Holders
- 4 Exhibit 4: Subscription Agreement
- 11 Exhibit 11: Accountant's Consent
- 8 Exhibit 8: Escrow Agreement
- 12 Exhibit 12: Attorney Letter Certifying Legality
- 13 Exhibit 13A: Testing the Waters Materials 1
- 13 Exhibit 13B: Testing the Waters Materials 2
- 13 Exhibit 13C: Testing the Waters Materials 3
Associated filings
- 11 Oct 22 QUALIF Notice of qualification
- 7 Oct 22 1-A POS Offering $40.00 mm in Equity
- 19 Sep 22 1-A POS Offering $40M in Equity
- 22 Aug 22 QUALIF Notice of qualification
- 8 Aug 22 1-A POS Offering $40M in Equity
- 29 Jul 22 QUALIF Notice of qualification
- 21 Jul 22 1-A/A Offering $40M in Equity
-
9 May 22 1-A Offering $40M in Equity
Facible BioDiagnostics similar filings
Filing view
External links
CONSENT OF INDEPENDENT AUDITOR
We consent to the use, in this Offering Circular on Form 1-A, of our independent auditor’s report dated March 28, 2022, with respect to the audited balance sheets of FACible BioDiagnostics LLC as of December 31, 2021 and 2020, and the related statements of operations, changes in stockholders’ equity, cash flows and related notes to the financial statements for the years then ended.
Very truly yours,
Assuarance Dimensions
/s/ Assurance Dimensions
Tampa, Florida
May 9, 2022